Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India.
School of Medical Science and Research, Sharda University, Greater Noida, Uttar Pradesh, India.
Pediatr Dermatol. 2023 Jul-Aug;40(4):627-632. doi: 10.1111/pde.15355. Epub 2023 Jun 3.
Moisturizers are first-line therapy for treatment of atopic dermatitis (AD). Although there are multiple types of moisturizers available, head-to-head trials between different moisturizers are limited.
To evaluate if a paraffin-based moisturizer is as effective as ceramide-based moisturizer in children with AD.
In this double-blind, randomized comparative trial of pediatric patients with mild to moderate AD, subjects applied either a paraffin-based or ceramide-based moisturizer twice daily. Clinical disease activity using SCOring Atopic Dermatitis (SCORAD), quality of life using Children/Infants Dermatology Life Quality Index (CDLQI/IDLQI), and transepidermal water loss (TEWL) were measured at baseline and at follow-up at 1, 3, and 6 months.
Fifty-three patients were recruited (27 ceramide group and 26 paraffin group) with a mean age of 8.2 years and mean disease duration of 60 months. The mean change in SCORAD at 3 months in the ceramide-based and paraffin-based moisturizer groups was 22.1 and 21.4, respectively (p = .37). The change in CDLQI/IDLQI, TEWL over forearm and back, amount and days of topical corticosteroid required, median time to remission and disease-free days at 3 months were similar in both groups. As the 95% confidence interval (CI) of mean change in SCORAD at 3 months in both groups (0.78, 95% CI: -7.21 to 7.52) was not within the predefined margin of equivalence (-4 to +4), the conclusion of equivalence could not be proven.
Both the paraffin-based and ceramide-based moisturizers were comparable in improving the disease activity in children with mild to moderate AD.
保湿剂是特应性皮炎(AD)治疗的一线疗法。虽然有多种类型的保湿剂可供选择,但不同保湿剂之间的头对头试验有限。
评估石蜡基保湿剂在 AD 患儿中的疗效是否与神经酰胺基保湿剂相当。
在这项针对轻中度 AD 儿科患者的双盲、随机对照试验中,受试者每天两次使用石蜡基或神经酰胺基保湿剂。在基线和 1、3 和 6 个月的随访时,使用 Scoring Atopic Dermatitis(SCORAD)评估临床疾病活动度,使用儿童皮肤病生活质量指数(CDLQI/IDLQI)评估生活质量,使用经表皮水分丢失(TEWL)评估。
共招募了 53 名患者(27 名神经酰胺组和 26 名石蜡组),平均年龄为 8.2 岁,平均病程为 60 个月。神经酰胺基和石蜡基保湿剂组在 3 个月时 SCORAD 的平均变化分别为 22.1 和 21.4(p=0.37)。两组在 CDLQI/IDLQI、前臂和背部 TEWL、外用皮质类固醇的用量和天数、达到缓解的中位时间和 3 个月无疾病天数方面的变化相似。由于两组 3 个月时 SCORAD 平均变化的 95%置信区间(CI)(0.78,95%CI:-7.21 至 7.52)不在预设的等效性边界(-4 至+4)内,因此无法证明等效性的结论。
在改善轻中度 AD 患儿的疾病活动度方面,石蜡基和神经酰胺基保湿剂的疗效相当。